Stroke is one of the leading causes of death and disability worldwide. It happens when blood flow to the brain is blocked or reduced, which prevents brain cells from getting oxygen.
Many people who survive a stroke remain at high risk of having another one, especially in the first few months. Preventing a second stroke is therefore a key goal in medical care.
For many years, doctors have relied on medications called antiplatelet drugs, such as aspirin, to reduce the risk of another stroke. These drugs work by preventing blood cells from clumping together and forming clots.
While they can help, their effect is limited. When doctors try to increase protection by combining these drugs or using them for long periods, the risk of bleeding becomes higher. This bleeding risk is one of the biggest concerns in stroke treatment.
A new international study offers hope for a better option. Researchers have tested a new drug called asundexian, which may reduce the risk of stroke without increasing the risk of serious bleeding. The results of this large study were published in The New England Journal of Medicine.
The study, known as the OCEANIC-STROKE trial, included 12,327 adults from 37 countries. All participants had recently experienced a stroke or a transient ischemic attack, often called a mini-stroke. These events were caused by blood clots that did not come from the heart, which is the most common type of stroke.
Participants joined the study within 72 hours of their event. They were randomly given either asundexian or a placebo, in addition to standard treatment like aspirin. The average age of participants was 68, and a significant number were older adults. Both men and women were included, making the study more representative of real patients.
The results were encouraging. About 6.2 percent of people taking asundexian had another stroke, compared to 8.4 percent in the placebo group. This means the drug reduced the risk of stroke by about 26 percent. It also lowered the risk of major heart-related problems, including heart attack and death, by 17 percent.
Even more importantly, the drug reduced severe strokes that lead to disability or death by 31 percent. At the same time, it did not increase the risk of serious bleeding, which is a major advantage over current treatments.
The reason for this difference lies in how the drug works. Most current blood-thinning drugs affect many parts of the clotting system, which can increase bleeding risk. Asundexian works in a more targeted way. It blocks a protein called Factor XIa, which plays a role in forming harmful clots but is less important for stopping bleeding.
By targeting this specific protein, the drug aims to prevent dangerous clots while allowing the body to maintain its ability to stop bleeding when needed. This approach represents a new way of thinking about blood clot prevention.
Despite these promising results, there are some limitations. The drug is still being studied and has not yet been approved for general use. Long-term safety and effectiveness still need to be confirmed. It is also important to study how the drug performs in different populations and healthcare settings.
In conclusion, this study shows that asundexian could become a safer and more effective option for preventing repeat strokes. It offers a potential breakthrough in stroke care by reducing risk without adding harm. However, more research is needed before it becomes widely available.
If you care about stroke, please read studies about how to eat to prevent stroke, and diets high in flavonoids could help reduce stroke risk.
For more health information, please see recent studies about how Mediterranean diet could protect your brain health, and wild blueberries can benefit your heart and brain.
Source: OCEANIC-STROKE trial.
